With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders

Kyle LaHucik

Senior Reporter

Roivant Sciences has added another branch to its family tree, unveiling Covant Therapeutics with a $10 million upfront commitment from Boehringer Ingelheim to turn up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

With Boehringer In­gel­heim’s help, Roivant churns out an­oth­er Vant to go up against En­deav­or, Im­pact founders

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders